NATCO Pharma announced the immediate launch of its generic Semaglutide multi-dose vials in India following patent expiry. The injection, used for Type 2 diabetes management, is priced starting at an MRP of INR 1,290 for the lowest strength. NATCO claims this offering is the most affordable GLP-1 therapy in the market, being up to 90% cheaper than the innovator’s brand, significantly increasing patient accessibility.
Immediate Launch of Generic Semaglutide Vials
NATCO Pharma Limited confirmed the launch of its generic Semaglutide Injection (multi-dose vials) in the Indian market on March 21, 2026, immediately following the patent expiry date. The product has received approval from the Central Drugs Standard Control Organisation (CDSCO) for multi-dose vials and pen devices based on a clinical comparison study.
Aggressive Pricing Strategy
NATCO is introducing Semaglutide under the brand names SEMANAT™ and SEMAFULL™. The multi-dose vials are being launched at highly competitive prices to ensure maximum patient reach:
- 2mg/1.5ml & 4mg/3ml: MRP of INR 1,290 per month.
- 8mg/3ml: MRP of INR 1,750 per month.
NATCO highlights that this vial dosage form is the most affordable GLP-1 therapy available, costing approximately 70% less than the pen device equivalent and 90% less than the innovator’s brand price. NATCO is the first company to offer generic Semaglutide in the vial dosage form in India, complete with customised syringes.
Future Pen Device Launch
The company also plans to launch the Semaglutide pen device later in April 2026, with prices set as follows:
- 2mg/1.5ml pen: MRP of INR 4,000 per month.
- 4mg/3ml pen: MRP of INR 4,200 per month.
- 8mg/3ml pen: MRP of INR 4,500 per month.
Business Strategy
As part of its commercial strategy, NATCO is also offering the generic Semaglutide product to third parties for co-marketing purposes. The Company, headquartered in Hyderabad, is a leading R&D-oriented pharmaceutical player focused on oncology and specialty molecules for global markets.
Source: BSE
